QBiotics Group
Business Services · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
PO Box 166, Yungaburra, Queensland, 4884...Phone Number
+61 738708933Website
www.qbiotics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About QBiotics Group
QBiotics is a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals. Their lead oncology product, tigilanol tiglate, has potential to treat a broad range of solid tumors and is marketed as STELFONTA for treatment of canine mast cell tumors. They are based in Yungaburra, Australia.Explore more
QBiotics Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is QBiotics Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once QBiotics Group has new funding data
QBiotics Group, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at QBiotics Group
Product Launch: Get notified when QBiotics Group launches new products
Click to see if QBiotics Group had a recent Job posting/layoffs
Check out if QBiotics Group is spiking on competitors!
Earning: See what the market has to say on QBiotics Group recently announced quarterly report
Check if QBiotics Group has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined QBiotics Group as Masked Content
Find 3 more new buyers
Compare Similar Companies to QBiotics Group
Compare insights from companies similar to QBiotics Group, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
QBiotics Group is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
QBiotics Group is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about QBiotics Group.
QBiotics Group financials insights
Gather financial insights about QBiotics Group, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$85M
QBiotics Group Tech Stack
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Funding
QBiotics Group News & Media
QBiotics welcomes Stephen Doyle as Chief Executive Officer
QBiotics, Australian life sciences company, specialising in small cell signaling molecules. Established programs in oncology (tigilanol tiglate), wound healing (EBC-1013), plus preclinical antibiotics. Drug discovery platform Ecologic and Phenotypic drug screening.QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION
BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited (QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce that Richard Godfrey will present to potential partners and investors at the Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention, both being held in the US through June 2023. Mr Godfrey, representing QBiotics in Business Development, LicensiUS FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL
Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS) The open label trial will evaluate efficacy and dose ranging in patients with advanced or...Get In Touch With QBiotics to Discuss Its Positive Solid Tumor Efficacy Data and Phase II Clinical Program at Bio 2022
Brisbane, Australia--(Newsfile Corp. - June 1, 2022) - Australian life science company, QBiotics will showcase positive efficacy data from its completed phase I trial of lead cancer molecule, tigilanol tiglate, and its Phase II clinical program at Bio 2022, the world's largest gathering of biotechnology and pharma leaders. To view the full announcement, including downloadable images, bios,...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding QBiotics Group
Sign Up For FreeTo access detailed company insights
QBiotics is a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals. Their lead oncology product, tigilanol tiglate, has potential to treat a broad range of solid tumors and is marketed as STELFONTA for treatment of canine mast cell tumors. They are based in Yungaburra, Australia.... Read More
